Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

Venetoclax (ven)+azacitidine (aza) is the standard of care for newly-diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy (IC). Because prognostic factors for ven/aza and IC differ, an AML patient fit for IC may derive more benefit from ven/aza. We there...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Justin Watts, Ellen Madarang, Diana Abbott, Payton Hart, Connor Sohalski, Alessia Zoso, Jessie Dell-Martin, Ayele Belachew, Maria L. Amaya, Andrew Kent, Christine McMahon, Marc Schwartz, Mikkael A. Sekeres, Clayton Smith, Terrence Bradley, Justin Taylor, Namrata Chandhok, Sangeetha Venugopal, Craig Jordan, Mary Berg, Mary Haag, Nicholas Willard, Dara Aisner, Jeffrey Schowinsky, Zenggang Pan, Jinjing Zhang, Jonathan A. Gutman, Daniel A. Pollyea
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2026-02-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/13186
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!